Author(s): Vessillier S, Eastwood D, Fox B, Sathish J, Sethu S, et al.
The therapeutic monoclonal antibody (mAb) TGN1412 (anti-CD28 superagonist) caused near-fatal cytokine release syndrome (CRS) in all six volunteers during a phase-I clinical trial. Several cytokine release assays (CRAs) with reported predictivity for TGN1412-induced CRS have since been developed for the preclinical safety testing of new therapeutic mAbs. The whole blood (WB) CRA is the most widely used, but its sensitivity for TGN1412-like cytokine release was recently criticized. In a comparative study, using group size required for 90% power with 5% significance as a measure of sensitivity, we found that WB and 10% (v/v) WB CRAs were the least sensitive for TGN1412 as these required the largest group sizes (n = 52 and 79, respectively). In contrast, the peripheral blood mononuclear cell (PBMC) solid phase (SP) CRA was the most sensitive for TGN1412 as it required the smallest group size (n = 4). Similarly, the PBMC SP CRA was more sensitive than the WB CRA for muromonab-CD3 (anti-CD3) which stimulates TGN1412-like cytokine release (n = 4 and 4519, respectively). Conversely, the WB CRA was far more sensitive than the PBMC SP CRA for alemtuzumab (anti-CD52) which stimulates FcγRI-mediated cytokine release (n = 8 and 180, respectively). Investigation of potential factors contributing to the different sensitivities revealed that removal of red blood cells (RBCs) from WB permitted PBMC-like TGN1412 responses in a SP CRA, which in turn could be inhibited by the addition of the RBC membrane protein glycophorin A (GYPA); this observation likely underlies, at least in part, the poor sensitivity of WB CRA for TGN1412. The use of PBMC SP CRA for the detection of TGN1412-like cytokine release is recommended in conjunction with adequately powered group sizes for dependable preclinical safety testing of new therapeutic mAbs.
Referred From: https://doi.org/10.1016/j.jim.2015.04.020
Author(s): Chin KL, Anis FZ, Sarmiento ME, Norazmi MN, Acosta A, et al.
Author(s): Negishi H, Taniguchi T, Yanai H
Author(s): Di Franco S, Turdo A, Todaro M, Stassi G
Author(s): Bessis N, GarciaCozar FJ, Boissier MC
Author(s): Sakurai H, Kawabata K, Sakurai F, Nakagawa S, Mizuguchi H, et al.
Author(s): Burel SA, Machemer T, Ragone FL, Kato H, Cauntay P, et al.
Author(s): Lennox KA, Behlke MA
Author(s): Leeds JM, Henry SP, Geary R, Burckin T, Levin AA, et al.
Author(s): Behlke MA
Author(s): Jacobi AM, Rettig GR, Turk R, Collingwood MA, Zeiner SA, et al.
Author(s): Neun BW, Dobrovolskaia MA
Author(s): Neun BW, Dobrovolskaia MA
Author(s): Potter TM, Neun BW, Rodriguez JC, Ilinskaya AN, Dobrovolskaia MA, et al.
Author(s): Fennrich S, Hennig U, Toliashvili L, Schlensak C, Wendel HP, et al.
Author(s): Coch C, Luck C, Schwickart A, Putschli B, Renn M, et al.
Author(s): Daneshian M, Von Aulock S, Hartung T
Author(s): Dobrovolskaia MA
Author(s): Hasiwa N, Daneshian M, Bruegger P, Fennrich S, Hochadel A, et al.
Author(s): Hoffmann S, Peterbauer A, Schindler S, Fennrich S, Poole S, et al.
Author(s): Alvarez-Salas LM
Author(s): Henry SP, Geary RS, Yu R, Levin AA
Author(s): Holmlund JT, Monia BP, Kwoh TJ, Dorr FA
Author(s): Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, et al.
Author(s): Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA
Author(s): Keefe AD, Pai S, Ellington A
Author(s): Schmidt A, Schwerd T, Hamm W, Hellmuth JC, Cui S, et al.